Lenalidomide/Rituximab Induces Durable Responses in Mantle Cell Lymphoma in 9-Year Follow-Up
The combination of lenalidomide and rituximab led to a median progression-free survival of 9 years—with 17 ongoing responses—among patients with mantle cell lymphoma.
Fixed-Duration Ibrutinib/Venetoclax Improves PFS in Patients With CLL and High-Risk Genomic Features
The complete response or complete response with incomplete bone marrow recovery rate was 61% for patients with chronic lymphocytic leukemia and high-risk disease.
Circulating Tumor DNA May Help Identify Early Responses in CRC
Circulating tumor DNA can be an effective biomarker that allows for assessments of early response.
Caressa Valdueza Highlights Best Practices for the Management of Common Adverse Events in Melanoma
Caressa Valdueza, MSN, AGNP-BC, AOCNP, discusses toxicity management with unfolding treatment options in melanoma.
Real-World Study Demonstrates Benefits with Adjuvant Nivolumab in Resected Stage IIIA Melanoma
A significant portion of patients with resected stage IIIA melanoma were alive and recurrence free at a median follow-up of over 20 months following treatment with adjuvant nivolumab.
Discrepancies Exist Between Actual Care and Trial-Based Recommendations in MCL
Discrepancies exist between actual patterns of care and recommendations based on clinical trials in adult patients with mantle cell lymphoma.
Azacitidine Improves Survival Outcomes, Quality of Life in AML
Oral azacitidine improved overall survival and relapse-free survival, while maintaining health-related quality of life in patients with acute myeloid leukemia.
Novel Agents, Earlier Diagnosis Driving Survival Gains in CLL
The median overall survival for patients with chronic lymphocytic leukemia has more than tripled since the 1970s, primarily due to an ever-expanding armamentarium of novel agents and earlier diagnosis.
Sandra Allen-Bard on Quality of Life Issues for Patients with MPN
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Maureen E. Thyne Discusses Ruxolitinib's Impact on Myelofibrosis
Maureen E. Thyne, RPA-C, Weill Cornell Medical College, discusses the impact that ruxolitinib (Jakafi) has had on patients with myelofibrosis.
Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care
Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs
Safety Management With Amivantamab Plus Lazertinib in NSCLC
